Russell Investments Group, Ltd. Clovis Oncology, Inc. Transaction History

Russell Investments Group, Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 05, 2022	SELL	$1.43 - $3.14 $212,612 - $466,855	-148,680 Closed	0 $0
Q4 2021 Jan 21, 2022	SELL	$2.7 - $4.76 $60,666 - $106,952	-22,469 Reduced 13.13%	148,680 $401,000
Q2 2021 Aug 04, 2021	BUY	$5.02 - $7.05 $505,022 - $709,244	100,602 Added 142.6%	171,149 $992,000
Q1 2021 May 10, 2021	BUY	$4.81 - $10.34 $339,331 - $729,455	70,547 New	70,547 $494,000
Q1 2019 May 13, 2019	SELL	$17.66 - $30.28 $297,111 - $509,430	-16,824 Closed	0 $0
Q4 2018 Feb 11, 2019	SELL	$11.63 - $32.67 $11,932 - $33,519	-1,026 Reduced 5.75%	16,824 $302,000
Q3 2018 Oct 26, 2018	SELL	$29.37 - $49.48 $387,184 - $652,294	-13,183 Reduced 42.48%	17,850 $525,000
Q1 2018 May 11, 2018	BUY	$50.12 - $67.72 $508,918 - $687,628	10,154 Added 48.63%	31,033 $1.64 Million
Q4 2017 Feb 06, 2018	SELL	$57.69 - $84.58 $781,468 - $1.15 Million	-13,546 Reduced 39.35%	20,879 $1.42 Million
Q3 2017 Nov 07, 2017	BUY	$67.17 - $84.81 $2.31 Million - $2.92 Million	34,425	34,425 $2.84 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.